Acrivon Therapeutics, Inc. (ACRV)
NASDAQ: ACRV · IEX Real-Time Price · USD
-0.16 (-1.97%)
At close: May 24, 2024, 4:00 PM
+0.39 (4.91%)
After-hours: May 24, 2024, 7:21 PM EDT

Company Description

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform.

The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.

Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer.

The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor.

Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.

Acrivon Therapeutics, Inc.
Acrivon Therapeutics logo
Country United States
Founded 2018
IPO Date Nov 15, 2022
Industry Biotechnology
Sector Healthcare
Employees 58
CEO Dr. Peter Blume-Jensen M.D., Ph.D.

Contact Details

480 Arsenal Way, Suite 100
Watertown, Massachusetts 02472
United States
Phone 617-207-8979

Stock Details

Ticker Symbol ACRV
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $12.50
CIK Code 0001781174
CUSIP Number 004890109
ISIN Number US0048901096
Employer ID 82-5125532
SIC Code 2834

Key Executives

Name Position
Dr. Peter Blume-Jensen M.D., Ph.D. Co-Founder, Chairman of the Board, Chief Executive Officer, President and Acting Chief Scientific Officer
Kristina Masson M.B.A., Ph.D. Co-Founder, Executive Vice President of Business Operations, Site Head, Treasurer, Secretary and Director
Rasmus Holm-Jorgensen Chief Financial Officer
Dr. Eric J. Devroe Ph.D. Chief Operating Officer
Katharine Peterson CPA Vice President of Finance and Accounting
Dr. Adam D. Levy M.B.A., Ph.D. Senior Vice President and Head of Investor Relations and Corporate Affairs
Bruce Close Vice President of Quality and Compliance
Mary-Alice Miller J.D. Chief Legal Officer
Parvin Miah Vice President and Head of Human Resources
Dr. Erick Gamelin M.D., Ph.D. Chief Development Officer

Latest SEC Filings

Date Type Title
May 14, 2024 8-K Current Report
May 14, 2024 10-Q Quarterly Report
Apr 29, 2024 EFFECT Notice of Effectiveness
Apr 26, 2024 ARS Filing
Apr 26, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 26, 2024 DEF 14A Other definitive proxy statements
Apr 24, 2024 8-K Current Report
Apr 17, 2024 S-3 Registration statement under Securities Act of 1933
Apr 15, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Apr 11, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership